Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02398513
Other study ID # 15823
Secondary ID
Status Completed
Phase Phase 1
First received March 20, 2015
Last updated July 29, 2016
Start date April 2015
Est. completion date June 2016

Study information

Verified date July 2016
Source Bayer
Contact n/a
Is FDA regulated No
Health authority China: China Food and Drug adminstration
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to define the pharmacokinetic of Regorafenib administered orally as a single agent in Chinese patients with advance solid tumors.

The second objective include the evaluation of safety, tolerability, and efficacy of Chinese patents treated with Regorafenib


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date June 2016
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Signed informed consent (IC) obtained before any study specific procedure. Patients must be able to understand and be willing to sign the written informed consent

- Patients with histologically or cytologically confirmed,refractory,locally advanced or metastatic solid tumors who are not candidates for standard therapy or in whom the specific clinical indications for which Regorafenib is approved elsewhere in the world is considered an appropriate treatment option.

- Male or female Chinese patients living in China mainland >= 18 years

- Patients must have measurable or non-measurable disease according to RECIST, version 1.1

- Eastern Cooperative Oncology Group performance status (ECOG-PS 0 - 1)

- Body mass index (BMI) between 18 and 33 kg/m2 inclusive

- Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to dosing:

- Platelet count >= 100,000/cubic millimeters (mm3), hemoglobin (Hb) >= 9 g/dl, leukocyte count > 3,000/mm3, absolute neutrophil count (ANC) >=1,500/mm3. Transfusion to meet the inclusion criteria will not be allowed.

- Total bilirubin <= 1.5 x the upper limit of normal (ULN).

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3.0 x ULN (<= 5 x ULN for patients with liver involvement of their cancer)

- Alkaline phosphatase limit <= 2.5 x ULN (<= 5 x ULN for patients whose cancer involves their liver and/or bone)

- Lipase <= 1.5 x ULN

- Serum creatinine <= 1.5 times ULN and estimated creatinine clearance (CLcr) >= 30 mL/min according to the Cockroft-Gault formula

- International normalized ratio (INR) <= 1.5 x ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) <= 1.5 x ULN. Patients being treated with anticoagulant, e.g. warfarin or heparin, will be allowed to participate provided no prior evidence of an underlying abnormality in these parameters exists. Close monitoring of at least weekly evaluations will be performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care.

- Life expectancy of at least 3 months.

- Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of study treatment, and a negative result must be documented before start of study treatment.

Exclusion Criteria:

- Prior treatment with Regorafenib

- Patients unable to swallow and retain oral medications

- Any other malignant disease treated < 3 years prior to study entry, except cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Staging: Ta, Tis and T1)

- Symptomatic metastatic brain or meningeal tumors if the patient is < 6 months from definitive therapy, has evidence of tumor growth on an imaging study within 4 weeks prior to study entry and is on dexamethasone and not clinically stable with respect to the tumor at the time of study entry.

- Major surgical procedure, or significant traumatic injury within 28 days before start of study medication

- History of organ allograft

- Non-healing wound, ulcer, or bone fracture

- Uncontrolled hypertension (systolic blood pressure >150 millimeter of mercury (mmHg) or diastolic blood pressure >90 mmHg despite optimal medical management)

- Persistent proteinuria > 3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (>=Grade 3, NCI-CTCAE v 4.03).

- History of cardiac disease: congestive heart failure (CHF) >=NYHA (New York Heart Association) Class II. Active coronary artery disease unstable angina (angina symptoms at rest) or new-onset angina (within last 3 months) or myocardial infarction (MI) within past 6 months

Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Regorafenib (Stivarga, BAY73-4506)
Regorafenib 160 mg per oral

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax (maximum drug concentration in plasma) Cycle 0 day 1, 0?0.5?1?2?3?4?6?8?12?24?36?48?72?96 hours No
Primary AUC(0-24) (AUC from time 0 h to time 24 h post-administration) Cycle 0 day1, 0?0.5?1?2?3?4?6?8?12?24 hours No
Primary AUC(0-tlast) (AUC from time zero to the last data point>LLOQ) Cycle0 day 1, 0?0.5?1?2?3?4?6?8?12?24?36?48?72?96 hours No
Primary Cmax.ss (Cmax at steady-state during a dosage interval) Cycle 1 day 21, 0,0.5,1,2,3,4,6,8,12,24,36,48,72,96 hours No
Primary AUCt.ss (AUC for the dosing interval at steady-state) cycle 1 day 21 0,0.5,1,2,3,4,6,8,12,24 hours No
Secondary Number of participants with adverse events as a measure of safety and tolerability Up to 30 days Yes
Secondary Tumor Response base don RECIST 1.1 criteria Up to 30 days No
See also
  Status Clinical Trial Phase
Completed NCT01439152 - Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Phase 1
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Active, not recruiting NCT06015009 - Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers N/A
Active, not recruiting NCT03298100 - Risk Scoring Model for Endometrial Cancer
Recruiting NCT05055609 - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Phase 1
Not yet recruiting NCT04324320 - Psychological Distress in Outpatient Oncological Rehabilitation
Completed NCT00588289 - Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA N/A
Recruiting NCT06222801 - The 1st Tumor CytokinoTherapy Database (TCTD-1)
Recruiting NCT03831633 - Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients Phase 4
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting NCT05198570 - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Recruiting NCT05712174 - A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer Phase 2
Recruiting NCT03832062 - Value of Analysing Under-utilised Leftover Tissue (VauLT)
Completed NCT03988777 - Magnetic Seed Localisation for Nonpalpable Breast Lesions
Recruiting NCT06031233 - Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie Phase 4
Enrolling by invitation NCT04019119 - Digital Intervention for the Modification of Lifestyles (iGame) N/A
Not yet recruiting NCT05926362 - Capillary-Venous Paired Data Collection
Recruiting NCT05686213 - ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial Phase 2
Recruiting NCT05510856 - Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients Phase 4
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors